American Journal of Kidney Diseases
Volume 50, Issue 2 , Pages 184-187 , August 2007

Effects of Tolvaptan, an Oral Vasopressin V2 Receptor Antagonist, in Hyponatremia

  • Nicolaos E. Madias, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Nicolaos E. Madias, MD, Department of Medicine, Caritas St. Elizabeth’s Medical Center, Tufts University School of Medicine, 736 Cambridge Street, Boston, MA 02135.

References 

  1. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med. 2006;119(suppl 1):S30–S35
  2. Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med. 2006;119:71.e1–71.e8
  3. Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–1589
  4. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–2112
  5. Astellas Pharma US, Inc: Vaprisol (conivaptan hydrochloride injection) product monograph. Deerfield, IL, 2006
  6. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006;69:2124–2130
  7. Palm C, Pistrosch F, Herbrig K, Gross P. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med. 2006;119(suppl 1):S87–S92
  8. Gerbes AL, Gülberg V, Ginès P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. Gastroenterology. 2003;124:933–939
  9. Soupart A, Gross P, Legros J-J, et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol. 2006;1:1154–1160
  10. Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials. JAMA. 2007;297:1332–1343
  11. Feldman BJ, Rosenthal SM, Vargas GA, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med. 2005;352:1884–1890
  12. Decaux G, Vandergheynst F, Bouko Y, Parma J, Vassart G, Vilain C. Nephrogenic syndrome of inappropriate antidiuresis in adults: High phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol. 2007;18:606–612
  13. Soupart A, Silver S, Schroeder B, Sterns R, Decaux G. Comparison of mortality and brain composition in hyponatremic rats treated with vasopressin V1-V2 receptor antagonists or water diuresis. J Am Soc Nephol. 2003;14:A747;(abstr)

PII: S0272-6386(07)00940-7

doi: 10.1053/j.ajkd.2007.06.011

American Journal of Kidney Diseases
Volume 50, Issue 2 , Pages 184-187 , August 2007

Article Tools